Skip to the page

Data / Drug companies / Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited: 97 products in the FDA NDC directory, labeler code 71209

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Cadila Pharmaceuticals Limited (labeler code 71209) lists 97 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 97 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 22, 2026.

The request: Watch Cadila Pharmaceuticals Limited (FDA labeler code 71209): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
71209
Products in commercial distribution
97
Packages
242
Finished drugs by generic name
30
Prescription products
97
Over the counter products
0
Controlled substance products
Schedule V 8
Flagged as original packager
87 of 87 products that carry the flag
Started marketing in the last 12 months
4
Earliest marketing start
February 10, 2014
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)97100%

Products by type

TypeProductsShare
Prescription drugs97100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet2828.9%
Tablet, film coated2525.8%
Capsule2323.7%
Tablet, coated1313.4%
Tablet, film coated, extended release33.1%
Tablet, extended release33.1%
For suspension22.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Amlodipine and valsartan71209-024Tablet, film coatedGeneric drugs (ANDA)October 22, 2026
Amlodipine and valsartan71209-023Tablet, film coatedGeneric drugs (ANDA)October 22, 2026
Amlodipine and valsartan71209-022Tablet, film coatedGeneric drugs (ANDA)October 22, 2026
Amlodipine and valsartan71209-021Tablet, film coatedGeneric drugs (ANDA)October 22, 2026
Olmesartan Medoxomil71209-081Tablet, coatedGeneric drugs (ANDA)January 1, 2025
Olmesartan Medoxomil71209-080Tablet, coatedGeneric drugs (ANDA)January 1, 2025
Olmesartan Medoxomil71209-079Tablet, coatedGeneric drugs (ANDA)January 1, 2025
Sildenafil71209-108Tablet, film coatedGeneric drugs (ANDA)December 1, 2023
Sildenafil71209-107Tablet, film coatedGeneric drugs (ANDA)December 1, 2023
Sildenafil71209-106Tablet, film coatedGeneric drugs (ANDA)December 1, 2023
Pregabalin71209-039CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-038CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-037CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-036CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-035CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-034CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-033CapsuleGeneric drugs (ANDA)July 13, 2023
Pregabalin71209-032CapsuleGeneric drugs (ANDA)July 13, 2023
Fluoxetine71209-042CapsuleGeneric drugs (ANDA)December 15, 2022
Fluoxetine71209-041CapsuleGeneric drugs (ANDA)December 15, 2022
Fluoxetine71209-040CapsuleGeneric drugs (ANDA)December 15, 2022
Erythromycin ethylsuccinate71209-103For suspensionGeneric drugs (ANDA)November 21, 2022
Erythromycin ethylsuccinate71209-102For suspensionGeneric drugs (ANDA)November 21, 2022
Erythromycin71209-101Tablet, film coatedGeneric drugs (ANDA)October 6, 2021
Erythromycin71209-100Tablet, film coatedGeneric drugs (ANDA)October 6, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.